Related Experiment Video

Updated: May 1, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

11.2K

Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools

Lucio Boglione1, Amedeo De Nicolò1, Giovanni Di Perri1

  • 1Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy.

Journal of Hepatology
|March 26, 2014
PubMed
Summary

No abstract available in PubMed .

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K

Related Experiment Videos

Last Updated: May 1, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

11.2K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

43.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.0K
Hepatitis01:25

Hepatitis

86
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86

Articles linked to this work by shared authors, journal, and citation graph.

Precision Redosing of Oritavancin: A Population Pharmacokinetic Framework to Optimize Long-Term Therapy for Complex Gram-Positive Infections.

International journal of antimicrobial agents·2026

Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring.

JAC-antimicrobial resistance·2026

Rapid achievement of protective cabotegravir concentrations in a real-world HIV PrEP cohort.

International journal of antimicrobial agents·2026

Real-World Evidence: Cefiderocol Therapeutic Drug Monitoring in Critically Ill, Obese Patients with Klebsiella pneumoniae Infections.

Antibiotics (Basel, Switzerland)·2026

Amoxicillin bone penetration in patients with medication-related osteonecrosis of the jaw: A preliminary study.

International journal of antimicrobial agents·2026

Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature.

Cancer chemotherapy and pharmacology·2026

Corticosteroid Therapy for Drug-induced Liver Injury: Mind the Gap!

Journal of hepatology·2026

Systemic therapy of biliary tract cancer: The road to personalised strategies.

Journal of hepatology·2026

Reproducibility of Biomarkers in MASLD: A Benchmark for Clinically Meaningful Change in Serially Measured Non-Invasive Tests.

Journal of hepatology·2026

The changing epidemiology of primary liver cancer in the 21st century.

Journal of hepatology·2026

Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction.

Journal of hepatology·2026

Non-selective β-blockers reduce bacterial translocation by restoring gut barrier function during experimental cirrhosis.

Journal of hepatology·2026

Hydrogel-Nanoparticle Bioactive Platforms for Post-Surgical Prevention of Tumor Recurrence.

Nanomaterials (Basel, Switzerland)·2026

FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Regulatory cascade of NdpR and NdpR2 in controlling nicotine degradation operons in Sphingomonas melonis TY.

Applied and environmental microbiology·2026

Epidermal growth factor receptor as a target enzyme in cancer therapy: Structural and functional insights from crystallography.

Indian journal of pharmacology·2026

Mitigating Breast Cancer with Intratumoral In Situ pH-responsive Abemaciclib-loaded Novasome Hydrogel.

Journal of drug targeting·2026

Mechanisms and Predisposing Conditions for Statin-Induced New-Onset Type 2 Diabetes Mellitus: A Paradox Relative to Their Pleiotropic Metabolic Effects.

Endocrinology, diabetes & metabolism·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us